ERBB2 and metastatic neoplasm: A total of 38.1% and 28.8% of patients with HER2-zero primary tumors exhibited HER2-low phenotype in metastatic tumors in the overall population and the HR− subtype, respectively, and the rate reached 48.4% in HR+ subtype.